Senescence-associated secretory phenotype (SASP)

There are 4,072 papers on senescence-associated secretory phenotype (SASP) in aging research: 32 trials and 381 observational studies in people, 1,268 in animals, 846 in cells, 1,463 reviews. The newest story, Nov 16, 2026: “Protein levels alter drug sensitivity in lab-grown human cells”.

ProcessCellular senescence

4,072 papers study it516 more mention it1,406 findings

MeSH

165 new papers in 30 daysSee all 4,588 papers on senescence-associated secretory phenotype (SASP)

At a glance

SASP induces senescence in human cells, which independent labs reproduce; independent labs also report fisetin reducing SASP in mice. One report instead describes senescence reducing SASP in human cells; SASP is associated with frailty in people with HIV. Some papers declare company ties, and some authors work at companies.

1,406 findings in 1,224 papers from 2008 to 2026, 238 of them since April 2026

Independent labs found the same change in cells, mice and people. 318 independent labs in 41 countries.

“Teeth achieving COM presented significantly lower amounts of SASP factors compared with non-successful teeth.”
Impact of Inflammatory Markers and Senescence-Associated Secretory Phenotype in the Gingival Crevicular Fluid on the Outcomes of Periodontal RegenerationInternational journal of molecular sciences2024doi:10.3390/ijms25126687

23 of its findings point the other way.

Cells, mice and humans: replicated by independent labs. Worms or flies: a single group.
  • 318 independent labs in 41 countries
  • 23 findings against
  • Funders: National Institutes of Health and others
  • 78 of 869 findings with company ties
  • Human trial32
  • Humans381
  • Animals1,257
  • Model organisms11
  • Cells846
  • In silico61

Interventions

213

Senomorphics

downin reviews19downin humans1

20 studies
  1. Senomorphics decrease senescence-associated secretory phenotype (SASP).

    “senomorphics, which suppress SASP without eliminating SC”

    Review

    Is there a role for senotherapeutics in the treatment of giant cell arteritis?

    Ageing research reviews

  2. Senomorphics inhibit senescence-associated secretory phenotype (SASP).

    “senomorphics, which suppress harmful senescent-cell functions, particularly senescence-associated secretory phenotype (SASP) signaling.”

    Review

    Senotherapeutics: emerging pharmacological strategies for targeting cellular senescence

    International Journal of Veterinary Sciences and Animal Husbandry

  3. Senomorphics decrease senescence-associated secretory phenotype (SASP).

    “Senomorphic compounds, including rapamycin, resveratrol, pterostilbene, urolithin A, and spermidine, reduce SASP activity”

    Review

    Molecular Mechanisms of Cellular Senescence and Targeted Intervention with Natural Bioactive Compounds

    Journal of Dermatologic Science and Cosmetic Technology

  4. Senomorphics inhibit senescence-associated secretory phenotype (SASP).

    “senomorphics that suppress SASP activity”

    Review

    The Role of Cellular Senescence in Chronic Lung Diseases: Emerging Mechanisms and Translational Perspectives: A Narrative Review

    Journal of Respiration

  5. Senomorphics inhibit senescence-associated secretory phenotype (SASP).

    “senomorphic agents offer a complementary therapeutic strategy by modulating the SASP without clearing the cells”

    Review

    Senomorphic agents: Multi-target strategies to tame the senescence-associated secretory phenotype for healthy ageing

    Experimental gerontology

  6. Senomorphics inhibit senescence-associated secretory phenotype (SASP).

    “A translational approach now involves either reducing the number of senescent cells using senolytics or inhibiting their SASP using senomorphics.”

    Review

    Misdirected intercellular communication in aging and chronic inflammation

    Zeitschrift fur Gerontologie und Geriatrie

  7. Senomorphics inhibit senescence-associated secretory phenotype (SASP).

    “Senomorphics precisely reshape the SASP profile by targeting signaling axis or interfering with epigenetic modifications.”

    Review

    Cleaning, Chasing and Calming: Promising Paradigms of Senotherapy in Aging-Related Diseases

    International journal of biological sciences

  8. Senomorphics inhibit senescence-associated secretory phenotype (SASP) in humans.

    “senomorphics, which modulate or suppress SASP activity without inducing senescent cell death.”

    Reviewskin

    Targeting cellular senescence in dermatology: senolytic and senomorphic strategies

    GeroScience

  9. Senomorphics decrease senescence-associated secretory phenotype (SASP).

    “senomorphics, which suppress the deleterious SASP without inducing cell death”

    Review

    Senotherapeutics: Emerging pharmacological strategies to target cellular senescence

    Advances in Translational Research

  10. Senomorphics inhibit senescence-associated secretory phenotype (SASP).

    “senomorphics (inhibiting the senescence-associated secretory phenotype, e.g., rapamycin)”

    Review

    Insights into the therapeutic strategies for aging and aging-associated diseases

    Signal transduction and targeted therapy

All 20

More on Senomorphics

Dasatinib + quercetin

downin mice7downin human cells4downin rats2downin cells1+1

15 studies
  1. Dasatinib + quercetin decreases senescence-associated secretory phenotype (SASP) in human fetal lung explants exposed to cannabinoids and nicotine.

    “The addition of senolytics, Dasatinib and Quercetin (D + Q), reduced the senescence-associated secretory phenotype (SASP), such as IL-6, IL-8, M-CSF, MCP-3, MIP-1β, TNFα, MIP-3β, and TSLP”

    Cellsin human fetal lung explants exposed to cannabinoids and nicotinelung

    Cannabis compounds and nicotine alter fetal lung cultures

    Pediatric research

  2. Dasatinib + quercetin decreases senescence-associated secretory phenotype (SASP) in cells.

    “Reduces senescence-associated secretory phenotype (SASP) factors including IL6, TNF-α, and MMPs”

    Cells

    Senolytic therapy targeting CDKN2A/TP53/SASP pathway with dasatinib-quercetin

    Zenodo (CERN European Organization for Nuclear Research)Preprint

  3. Dasatinib + quercetin decreases senescence-associated secretory phenotype (SASP) in cyclophosphamide-induced ovarian injury.

    “DQ therapy effectively mitigated CY-induced damage by clearing senescent cells and reducing SASP secretion.”

    Animalsin cyclophosphamide-induced ovarian injuryovaryfemales

    Senolytics alleviate cyclophosphamide-induced premature ovarian insufficiency by eliminating senescent cells

    European journal of histochemistry : EJH

  4. Dasatinib + quercetin decreases senescence-associated secretory phenotype (SASP) in rats after single 30 Gy right-lung irradiation.

    “suppressed multiple senescence-associated secretory phenotype (SASP) factors”

    Animalsafter single 30 Gy right-lung irradiationlung

    Dasatinib and quercetin mitigate radiation-induced lung injury by eliminating senescent cells in a rat model

    Frontiers in pharmacology

  5. Dasatinib + quercetin decreases senescence-associated secretory phenotype (SASP) in rats (aged rats with rotator cuff tear repair).

    “a significant decrease in the gene expression of senescence markers (p21 and p16) and senescence-associated secretory phenotype factors (IL-6, IL-1β, and MMP-3)”

    Animalsaged rats with rotator cuff tear repairsupraspinatus-humerus complex12 weeks after repairn = 24

    Senolytic Combination of Dasatinib and Quercetin Promotes Tendon-to-Bone Healing by Mitigating Age-Related Senescence in Rats

    The American journal of sports medicine

  6. Dasatinib + quercetin decreases senescence-associated secretory phenotype (SASP) in mice after global cerebral ischemia.

    “followed by decreased release of the potent inflammatory senescence-associated secretory phenotypes (SASP)”

    Animalsafter global cerebral ischemiahippocampus12 weeks

    Senolytic Treatment Attenuates Global Ischemic Brain Injury and Enhances Cognitive Recovery by Targeting Mitochondria

    Cellular and molecular neurobiology

  7. Dasatinib + quercetin decreases senescence-associated secretory phenotype (SASP) in mice (fertility-deficient mice).

    “reduces senescence-associated secretory phenotype (SASP) accumulation”

    Animalsfertility-deficient micenano-encapsulatedfemales

    Nano-encapsulated senolytic cocktail attenuates germ cell senescence in female mice

    Cellular and molecular life sciences : CMLS

  8. Dasatinib + quercetin decreases senescence-associated secretory phenotype (SASP) in mice (aged mice compared with young controls).

    “It also lowered the expression of SnCs, SASP, and neutrophil markers.”

    Animalsaged mice compared with young controlsalveolar bone

    Dasatinib and Quercetin Mitigate Age-Related Alveolar Bone Inflammaging and Neutrophil Infiltration

    Oral diseases

  9. Dasatinib + quercetin decreases senescence-associated secretory phenotype (SASP) in mice.

    “mitigated senescent cell burden and SASP in gingival tissues”

    Animalsgingiva

    Dasatinib and Quercetin Limit Gingival Senescence, Inflammation, and Bone Loss

    Journal of dental research

  10. Dasatinib + quercetin decreases senescence-associated secretory phenotype (SASP) in human dermal papilla culture.

    “reversed SASP accumulation and SASP-mediated repressive interactions in human DP culture”

    Cellsin human dermal papilla culture

    Restoration of hair follicle inductive properties by depletion of senescent cells

    Aging cell

All 15

More on Dasatinib + quercetin

Metformin

downin reviews3downin cells1downin human cells1downin mice1+1

7 studies
  1. Metformin inhibits senescence-associated secretory phenotype (SASP).

    “senomorphics, such as repurposed metformin and natural polyphenols that suppress the SASP”

    Review

    The Triad of Vascular Ageing: Cellular Senescence, Inflammaging, and Epigenetic Remodelling in Atherosclerosis

    Mechanisms of ageing and development

  2. Metformin decreases senescence-associated secretory phenotype (SASP) in mice (bleomycin-induced lung fibrosis).

    “decreased fibroblast release of senescence-associated secretory phenotype (SASP) factors”

    Animalsbleomycin-induced lung fibrosisi.p.lung65 mg/kg14 days

    B77-21 Senomorphic Effects of Metformin Promotes Resolution of Age-Associated Lung Fibrosis

    American Journal of Respiratory and Critical Care Medicine

  3. Metformin decreases senescence-associated secretory phenotype (SASP) in mouse cells.

    “metformin, a known anti-aging agent, attenuated SASP by enhancing NRF2/IRE1α-dependent UPR signaling in PDLSCs.”

    Cellsperiodontal ligament stem cell

    Metformin alleviates aging-associated periodontitis via NRF2-mediated restoration of the IRE1α dependent unfolded protein response

    Bioactive materials

  4. Metformin decreases senescence-associated secretory phenotype (SASP).

    “metformin has effectively suppressed cellular senescence and senescence-associated secretory phenotype (SASP) in age-related diseases (ARDs)”

    Review

    Senotherapeutic repurposing of metformin for age-related diseases and their signaling pathways

    Molecular biology reports

  5. Metformin decreases senescence-associated secretory phenotype (SASP) in cells (H2O2-induced senescence).

    “Metformin significantly decreased the expression of SASP in H2O2-induced senescent cells”

    CellsH2O2-induced senescence

    Metformin alleviates auditory cell senescence by mitophagy induction

    Neuroscience research

  6. Metformin decreases senescence-associated secretory phenotype (SASP) in vitro incubation with MET (1 mM × 106 B cells).

    “the expression of transcripts for SASP, and metabolic markers that support intrinsic B cell inflammation”

    Cellsin vitro incubation with MET (1 mM × 106 B cells)adipose tissue1 mMfemalesn = 8

    In Vitro Treatment with Metformin Significantly Reduces Senescent B Cells Present in the Adipose Tissue of People with Obesity

    The Journal of nutrition

  7. Metformin inhibits senescence-associated secretory phenotype (SASP).

    “senomorphic agents such as metformin which targets aspects of the senescence-associated secretory phenotype”

    Review

    Targeting Senescent Cells as Therapy for CKD

    Kidney360

More on Metformin

Extracellular vesicles

downin reviews2upin human cells1downin mice1downin mouse cells1

5 studies
  1. Extracellular vesicles inhibit senescence-associated secretory phenotype (SASP).

    “Extracellular vesicles (EVs), naturally derived nanoscale membrane vesicles capable of transporting diverse bioactive cargoes across tissues and biological barriers, have emerged as a highly promising platform for regenerative and anti-aging therapeutics.”

    Review

    Engineering Extracellular Vesicles for Anti-Aging Therapy: Mechanisms, Applications, and Perspectives

    Aging cell

  2. Extracellular vesicles decrease senescence-associated secretory phenotype (SASP) in mouse cells (functionalized with P3 peptide; in vitro).

    “effectively inhibits senescence-associated secretory phenotype (SASP) in both aged adipocytes and adipose explants in vitro”

    Cellsfunctionalized with P3 peptide; in vitrofunctionalized with P3 peptideadipose tissue

    Suppression of senescent metabolism of adipose tissue by rebalancing mitochondrial homeostasis via a selective drug delivery system

    Journal of nanobiotechnology

  3. Extracellular vesicles induce senescence-associated secretory phenotype (SASP) in human cells (plasma EVs from PLWH applied to HIV-uninfected PBMCs).

    “plasma EVs from PLWH predominantly induce SASP and drive IL-6 production in HIV-uninfected PBMCs.”

    Cellsplasma EVs from PLWH applied to HIV-uninfected PBMCsplasma-derivedperipheral blood mononuclear cells

    Extracellular Vesicles Favor Early Peripheral Immunosenescence Through Modulation of the Senescence-Associated Secretory Phenotype in HIV Infection

    Aging cell

  4. Extracellular vesicles decrease senescence-associated secretory phenotype (SASP).

    “therapies based on extracellular vesicles that specifically reduce SASP while maintaining cartilage health”

    Reviewcartilage

    Targeting the senescence-associated secretory phenotype to modify osteoarthritis in aging

    Inflammopharmacology

  5. Extracellular vesicles decrease senescence-associated secretory phenotype (SASP) in mice (diabetic mice).

    “In diabetic mice, the engineered EVs reduced systemic senescent cell burden and suppressed SASP factors.”

    Animalsdiabetic miceengineered, dasatinib and quercetin loaded

    Engineered bifunctional extracellular vesicles simultaneously promoting senolysis and efferocytosis for anti-aging therapy in diabetic mice

    Biochemical and biophysical research communications

More on Extracellular vesicles

Resveratrol

downin reviews2downin human cells1downin rats1

4 studies
  1. Resveratrol inhibits senescence-associated secretory phenotype (SASP).

    “curcumin and resveratrol exhibit the most extensive senotherapeutic activities, followed by ginsenosides, baicalin, myricetin, and other flavonoids, owing to their ability to target multiple senescence-associated signaling pathways and suppress the SASP”

    Review

    Anti-inflammatory phytochemicals from medicinal herbs based on senoinflammation schema for healthy aging

    Archives of pharmacal research

  2. Resveratrol decreases senescence-associated secretory phenotype (SASP) in pancreatic cancer model.

    “resveratrol reduces senescent CAFs and downregulates SASP factors, thereby disrupting the pro-tumorigenic activities of these cells.”

    Reviewin pancreatic cancer model

    Resveratrol: A promising agent in targeting senescent cancer-associated fibroblasts to inhibit pancreatic cancer progression

    World journal of gastrointestinal oncology

  3. Resveratrol decreases senescence-associated secretory phenotype (SASP) in CPCs from osteoarthritic cartilage.

    “Additionally, SASP-related genes and proteins (MMP-9, MMP13) and inflammatory mediators (IL-1β, TGF-β, and IL-6) were downregulated.”

    Cellsin CPCs from osteoarthritic cartilage

    Fisetin and resveratrol exhibit senotherapeutic effects and suppress cellular senescence in osteoarthritic cartilage-derived chondrogenic progenitor cells

    European journal of pharmacology

  4. Resveratrol inhibits senescence-associated secretory phenotype (SASP) in arsenic-exposed rats.

    “RSV counteracts arsenic-induced hepatocyte senescence and the release of SASP-related proteins”

    Animalsin arsenic-exposed ratsliver

    Resveratrol Alleviates Arsenic Exposure-Induced Liver Fibrosis in Rats by Inhibiting Hepatocyte Senescence

    Biological trace element research

More on Resveratrol

Fisetin

downin human cells2downin humans1downin mice1

4 studies
  1. Fisetin decreases senescence-associated secretory phenotype (SASP) in mice (doxorubicin-treated mice).

    “Fisetin mitigated excess vascular cell senescence and the SASP in young mice administered doxorubicin”

    Animalsdoxorubicin-treated miceintermittent oral supplementation100 mg/kg/day

    Fisetin Supplementation Attenuates Premature Vascular Aging Induced by Doxorubicin via Suppression of Cellular Senescence and Mitochondrial Oxidative Stress

    Aging cell

  2. Fisetin decreases senescence-associated secretory phenotype (SASP) in humans (preliminary human studies).

    “Preliminary human studies involving FOXO4-axis modulators, such as high-dose fisetin, show a reduction in the senescence-associated secretory phenotype (SASP)”

    Reviewpreliminary human studieshigh-dose

    Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline

    Naunyn-Schmiedeberg's archives of pharmacology

  3. Fisetin decreases senescence-associated secretory phenotype (SASP) in human cells (doxorubicin-induced senescence).

    “a significant reduction in IL-6 and IL-8 secretion in senescent cells”

    Cellsdoxorubicin-induced senescenceliposome-encapsulated

    Targeting Cellular Senescence with Liposome-Encapsulated Fisetin: Evidence of Senomorphic Effect

    International journal of molecular sciences

  4. Fisetin decreases senescence-associated secretory phenotype (SASP) in CPCs from osteoarthritic cartilage.

    “Additionally, SASP-related genes and proteins (MMP-9, MMP13) and inflammatory mediators (IL-1β, TGF-β, and IL-6) were downregulated.”

    Cellsin CPCs from osteoarthritic cartilage

    Fisetin and resveratrol exhibit senotherapeutic effects and suppress cellular senescence in osteoarthritic cartilage-derived chondrogenic progenitor cells

    European journal of pharmacology

More on Fisetin

Apigenin

downin cells1downin human cells1downin reviews1

3 studies
  1. Apigenin decreases senescence-associated secretory phenotype (SASP) in cells (LPS-exposed macrophages).

    “API inhibits DOT1L-mediated H3K79me2 enrichment to downregulate IL1A, thus reducing the SASP of macrophages.”

    CellsLPS-exposed macrophagesmacrophage

    Targeting senescence-associated secretory phenotype macrophage: apigenin inhibits DOT1L-dependent H3K79me2 at IL1A to fight SASP in senescent macrophages

    Frontiers in molecular biosciences

  2. Apigenin inhibits senescence-associated secretory phenotype (SASP) (senescent cells).

    “Specifically, it suppresses the senescence-associated secretory phenotype (SASP) by inhibiting key inflammatory signaling pathways such as NF-κB and p38-MAPK”

    Reviewsenescent cells

    Apigenin as a bioactive compound for longevity: Targets and mechanisms in senescent cells

    Bioactive Compounds in Health and Disease

  3. Apigenin prevents senescence-associated secretory phenotype (SASP) in human cells.

    “In senescent cells, apigenin blocks the interactions between ATM/p38 and HSPA8, thus preventing transition of the acute stress-associated phenotype (ASAP) towards the SASP.”

    Cells

    Repurposing the plant-derived compound apigenin for senomorphic effect in antiaging pipelines

    bioRxiv (Cold Spring Harbor Laboratory)Preprint

More on Apigenin

Radiation

no changein human cells1upin reviews1upin rhesus monkeys1

3 studies
  1. Radiation induces senescence-associated secretory phenotype (SASP) in rhesus monkeys (compared with control non-irradiated NHPs).

    “In BAL fluid that was collected from WTLI NHP senescence-associated secretory proteins (SASP) were significantly induced, compared to the BAL fluid collected from control non-irradiated NHPs.”

    Animalscompared with control non-irradiated NHPswhole-thorax lung irradiationbronchoalveolar lavage

    Radiation-induced Lung Injury (RILI) in Non-human Primates (NHPs) Induces Cellular Senescence and Upregulation of Tyrosine Kinase Fgr, which is Detectable in Bronchoalveolar Lavage

    Radiation research

  2. Radiation showed no clear effect on senescence-associated secretory phenotype (SASP) in osteochondral explants.

    “Irradiation upregulated CDKN1A, encoding p21, and downregulated LMNB1, representing a cell cycle arrest profile with the absence of a SASP response.”

    Cellsin osteochondral explantsosteochondral explant

    Development of Reliable and High-Throughput Human Biomimetic Cartilage and Bone Models to Explore Senescence and Personalized Osteoarthritis Treatment Options

    Journal of orthopaedic research : official publication of the Orthopaedic Research Society

  3. Radiation induces senescence-associated secretory phenotype (SASP).

    “manifestation of the senescence-associated secretory phenotype (SASP)”

    Review

    The Molecular Mechanisms in Senescent Cells Induced by Natural Aging and Ionizing Radiation

    Cells

More on Radiation

Selenium

downin chicken cells1downin human cells1

2 studies
  1. Selenium decreases senescence-associated secretory phenotype (SASP) in chicken cells (cadmium-induced ferroptotic stress).

    “Se restored GPX4 activity and reduced lipid peroxidation, thereby suppressing ferroptotic stress-associated macrophage senescence and SASP secretion”

    Cellscadmium-induced ferroptotic stressmacrophage

    Selenium alleviates cadmium-induced ovarian fibrosis by inhibiting macrophage senescence in chickens

    The Journal of nutritional biochemistry

  2. Selenium decreases senescence-associated secretory phenotype (SASP) in vitro expansion.

    “levels of ROS and senescence-associated secretory phenotype factors (IL-6 and IL-8).”

    Cellsin vitro expansionmesenchymal stem cells

    Effects of Different Forms of Selenium in Human Umbilical Cord Mesenchymal Stem Cells

    Biomedicines

More on Selenium

Quercetin

downin human cells2

2 studies
  1. Quercetin decreases senescence-associated secretory phenotype (SASP) in human cells (ex vivo intervertebral disc degeneration model).

    “The secretion of cytokines, chemokines and senescent factors was reduced in IVD cultures following treatment with all senolytics”

    Cellsex vivo intervertebral disc degeneration modelintervertebral disc tissue explants1 week

    TARGETING CELLULAR SENESCENCE TO COMBAT INTERVERTEBRAL DISC DEGENERATION AND OSTEOARTHRITIS

    Orthopaedic Proceedings

  2. Quercetin inhibits senescence-associated secretory phenotype (SASP) in IL-1β-induced chondrocytes.

    “quercetin treatment was associated with restored CDK1/CDK6 activity, reduced cell cycle arrest, downregulated IL6/TGF-β-mediated SASP”

    Cellsin IL-1β-induced chondrocytes

    Integrative transcriptomics and single-cell analysis unravel the senescence-reversing mechanism of quercetin in osteoarthritic chondrocytes

    Biochemical and biophysical research communications

More on Quercetin

Zoledronic acid

downin humans1

1 study
  1. Zoledronic acid decreases senescence-associated secretory phenotype (SASP) in humans (human trial proteomic analysis) (~400 proteins altered).

    “downregulation of proteins linked to genomic instability, proteostasis loss, mitochondrial dysfunction, stem cell exhaustion, and SASPs.”

    Human trialhuman trial proteomic analysis

    Blood protein levels changed after bone drug in older women

    Signal transduction and targeted therapy

More on Zoledronic acid

AG490

downin humans1

1 study
  1. AG490 decreases senescence-associated secretory phenotype (SASP) in humans (ex vivo tendon biopsies).

    “similarly to the senotherapeutic compound AG490”

    Human trialex vivo tendon biopsiestendon

    Occurrence of cellular senescence in chronic human shoulder tendinopathies and its attenuation ex vivo by inhibition of Enhancer of Zeste 2

    Bone & joint research

More on AG490

Tazemetostat

downin humans1

1 study
  1. Tazemetostat decreases senescence-associated secretory phenotype (SASP) in humans (ex vivo tendon biopsies).

    “Treatment of tendon biopsies with EPZ-6438 reduced secretion of a panel of SASP factors, including interleukin-6 (IL6), IL8, matrix metalloproteinase-3 (MMP3) or GRO1”

    Human trialex vivo tendon biopsiestendon

    Occurrence of cellular senescence in chronic human shoulder tendinopathies and its attenuation ex vivo by inhibition of Enhancer of Zeste 2

    Bone & joint research

More on Tazemetostat

Elective spinal reconstructive surgery

upin humans1

1 study
  1. Elective spinal reconstructive surgery increases senescence-associated secretory phenotype (SASP) in humans (elective spinal reconstructive surgery).

    “Senescence-associated secretory phenotype proteins were higher in older patients at baseline and further elevated during and after surgery.”

    Human trialelective spinal reconstructive surgeryplasma

    Transcriptomic and Proteomic Characterization of the Immune Response to Elective Spinal Reconstructive Surgery: Impact of Aging and Comparison with Traumatic Injury Response

    Journal of the American College of Surgeons

More on Elective spinal reconstructive surgery

All 213

Effects

144

Inflammation

upin reviews48upin humans7

55 studies
  1. Senescence-associated secretory phenotype (SASP) increases inflammation (Time- and context-dependent effects).

    “The senescence-associated secretory phenotype can propagate inflammation, matrix remodeling, and secondary senescence”

    ReviewTime- and context-dependent effects

    Cellular Senescence Phenotypes in Cardiovascular Aging: Mechanisms and Therapeutic Potential

    Clinical interventions in aging

  2. Senescence-associated secretory phenotype (SASP) increases inflammation (atherosclerosis).

    “The senescence-associated secretory phenotype (SASP) promotes vascular inflammation, extracellular matrix remodelling, and impaired clearance of apoptotic cells.”

    Reviewatherosclerosisvasculature

    CELLULAR SENESCENCE IN ATHEROSCLEROSIS: MOLECULAR MECHANISMS, PATHOGENIC SIGNIFICANCE, AND EMERGING PHARMACOLOGICAL STRATEGIES

    INTERNATIONAL JOURNAL OF ADVANCED SCIENTIFIC AND TECHNICAL RESEARCH

  3. Senescence-associated secretory phenotype (SASP) increases inflammation (sarcopenia).

    “SASP can promote persistent local inflammation, changes in immune cell function, and the spread of the senescent phenotype”

    Reviewsarcopenia

    Research advances in the senescence-associated secretory phenotype-mediated immune-inflammatory network in sarcopenia

    Geriatrics Research

  4. Senescence-associated secretory phenotype (SASP) increases inflammation (when senescent cells persist in cancer).

    “it can also promote chronic inflammation, immune suppression, stromal remodeling, recurrence and resistance when senescent cells persist.”

    Reviewwhen senescent cells persist in cancer

    Reshaping the tumor immune microenvironment via therapy-induced senescence: senescence-associated secretory phenotype networks and senolytic strategies

    Molecular biology reports

  5. Senescence-associated secretory phenotype (SASP) induces inflammation.

    “the senescence-associated secretory phenotype (SASP) orchestrates inflammaging and reprograms the CRC microenvironment via pro-inflammatory cytokines, chemokines, and growth factors.”

    Reviewcolorectal cancer microenvironment

    Immunosenescence in colorectal cancer: Interplay of microbiota, inflammaging, and metabolic reprogramming

    Cytokine & growth factor reviews

  6. Senescence-associated secretory phenotype (SASP) increases inflammation.

    “the secretion of the senescence-associated secretory phenotype (SASP), rich in proinflammatory cytokines and metalloproteinases, drive inflammaging and oxinflammaging.”

    Reviewskin

    Cutaneous inflammaging and cellular senescence: Molecular mechanisms of inflammatory skin aging and therapeutic targets

    Research Society and Development

  7. Senescence-associated secretory phenotype (SASP) increases inflammation in oral lichen planus.

    “senescent mesenchymal cells may amplify inflammation via SASP”

    Reviewin oral lichen planus

    T-cell senescence and immunosenescence in chronic oral mucosal inflammatory diseases: mechanisms and therapeutic implications

    Journal of oral microbiology

  8. Senescence-associated secretory phenotype (SASP) increases inflammation.

    “facilitates SASP activation, leading to neuroinflammation and neurodegeneration.”

    Reviewbrain

    Brain Aging and Cellular Senescence Trigger Neuroimmunological Dysregulation and Neurodegeneration

    Brain sciences

  9. Senescence-associated secretory phenotype (SASP) induces inflammation.

    “exhibit a senescence-associated secretory phenotype that can lead to propagation of inflammation, modification of immune-cell function, induce secondary senescence and promote extracellular matrix remodeling”

    Reviewkidney allograft

    Senescent Cells in Kidney Transplantation: Hidden Drivers of Graft Aging, Inflammation, and Long-Term Dysfunction

    KIDNEYS

  10. Senescence-associated secretory phenotype (SASP) increases inflammation.

    “persistent activity drives chronic low-grade inflammation and contributes to age-related diseases.”

    Review

    The vicious cycle of SASP and inflammaging promotes aging and age-related diseases

    Communications biology

All 55

More on Inflammation

Cellular senescence

upin cells4upin reviews3upin mouse cells2mediatesin human cells1+3

13 studies
  1. Senescence-associated secretory phenotype (SASP) induces cellular senescence in mouse cells (unirradiated cells exposed to irradiated fibroblast-derived SASP).

    “the irradiated fibroblast-derived SASP induced a senescent phenotype in unirradiated fibroblasts and macrophages.”

    Cellsunirradiated cells exposed to irradiated fibroblast-derived SASPfibroblasts and macrophages

    Drug reduced radiation-induced skin scarring in mice

    International journal of radiation oncology, biology, physics

  2. Senescence-associated secretory phenotype (SASP) induces cellular senescence in cells (paracrine effect on neighboring cells).

    “SASP factors from p21+ β cells induced secondary senescence in neighboring cells”

    Cellsparacrine effect on neighboring cells

    Senescent cells linked to poor insulin release in human islets

    JCI insight

  3. Senescence-associated secretory phenotype (SASP) induces cellular senescence.

    “senescence-associated secretory phenotype factors that act to propagate senescence signals to nearby and distant cells”

    Review

    Communication breakdown: senescent cells in interorgan communication of aging

    Trends in endocrinology and metabolism: TEM

  4. Senescence-associated secretory phenotype (SASP) mediates cellular senescence in human cells (paracrine spreading).

    “identified key SASP ligand-receptor pairs involved in this paracrine dissemination.”

    Cellsparacrine spreadingbrain

    Characterizing the SASP-Dependent Paracrine Spreading of Senescence Between Human Brain Cell Types

    bioRxiv : the preprint server for biologyPreprint

  5. Senescence-associated secretory phenotype (SASP) induces cellular senescence in neighbouring, uninfected cells.

    “propagating secondary senescence in neighbouring, uninfected cells through paracrine signalling”

    Cellsin neighbouring, uninfected cells

    Cell senescence emerges as a hallmark and therapeutic target of chronic intracellular infection

    Research SquarePreprint

  6. Senescence-associated secretory phenotype (SASP) mediates cellular senescence (dissemination of senescence from local to neighboring cells).

    “We focus on the SASP as the central executor of this systemic effect, disseminating local senescence”

    Reviewdissemination of senescence from local to neighboring cells

    Cellular senescence in age-related cardiovascular disease: past and future

    Frontiers in aging

  7. Senescence-associated secretory phenotype (SASP) induces cellular senescence.

    “It initially induces surrounding cells to enter a state of senescence through paracrine mechanisms”

    Review

    Immunoregulatory mechanisms in the aging microenvironment: Targeting the senescence-associated secretory phenotype for cancer immunotherapy

    Acta pharmaceutica Sinica. B

  8. Senescence-associated secretory phenotype (SASP) increases cellular senescence.

    “These SASP factors not only propagate the senescence phenotype but also disrupt bone homeostasis by impairing the functionality of bone tissue cells, thereby accelerating skeletal aging.”

    Reviewbone

    Mechanisms of aging-related secretory phenotype regulation in osteoporosis: Network regulation, trade-offs and homeostasis

    Pathology, research and practice

  9. Senescence-associated secretory phenotype (SASP) induces cellular senescence in cells.

    “The SASP from the Cdkn1a+ subpopulation induced secondary senescence and dysfunction in neighboring cells.”

    Cellssecondary senescence in neighboring cells, from the Cdkn1a+ senescent beta-cell subpopulationpancreatic islet

    Targeting β-Cell Senescence and Secondary Senescence—Therapeutic Potential of JAK Inhibitors in Diabetes

    ADA Scientific Sessions 2025 abstract

  10. Senescence-associated secretory phenotype (SASP) induces cellular senescence in cells (SASP factors from Cdkn1a+ cells, in vitro).

    “A subset of four SASP factors from Cdkn1a + cells was sufficient to induce secondary senescence and β-cell dysfunction in vitro.”

    CellsSASP factors from Cdkn1a+ cells, in vitro

    A human and mouse subpopulation of senescent β-cells induces pathologic dysfunction through targetable paracrine signaling

    bioRxiv : the preprint server for biologyPreprint

All 13

More on Cellular senescence

Extracellular matrix remodeling

upin reviews7downin humans1upin humans1mediatesin reviews1

10 studies
  1. Senescence-associated secretory phenotype (SASP) increases extracellular matrix remodeling (atherosclerosis).

    “The senescence-associated secretory phenotype (SASP) promotes vascular inflammation, extracellular matrix remodelling, and impaired clearance of apoptotic cells.”

    Reviewatherosclerosisvasculature

    CELLULAR SENESCENCE IN ATHEROSCLEROSIS: MOLECULAR MECHANISMS, PATHOGENIC SIGNIFICANCE, AND EMERGING PHARMACOLOGICAL STRATEGIES

    INTERNATIONAL JOURNAL OF ADVANCED SCIENTIFIC AND TECHNICAL RESEARCH

  2. Senescence-associated secretory phenotype (SASP) induces extracellular matrix remodeling.

    “senescent cells actively communicate with and remodel their tissue environment”

    Review

    Cellular senescence: six decades of discovery and reinvention

    The EMBO journal

  3. Senescence-associated secretory phenotype (SASP) mediates extracellular matrix remodeling (via immune cell recruitment, regulation of cell function, and modulation of ECM turnover).

    “The SASP, a dynamic cocktail composed of cytokines, chemokines, and proteases, remodels the intrahepatic microenvironment through immune cell recruitment, regulation of cell function, and modulation of ECM turnover.”

    Reviewvia immune cell recruitment, regulation of cell function, and modulation of ECM turnoverliver

    Context-dependent duality of senescent cells in liver fibrosis

    Liver research (Beijing, China)

  4. Senescence-associated secretory phenotype (SASP) impairs extracellular matrix remodeling in humans.

    “senescent dermal fibroblasts, keratinocytes and adipocytes secrete a chronic SASP that shifts the Matrix Metalloproteinase (MMP)/Tissue Inhibitor of Metalloproteinase (TIMP) balance toward net proteolysis”

    Review

    The Inflammaging Paradox in Aesthetic Surgery: How Systemic Senescence Blunts the Efficacy of Energy-Based Devices and Tissue Repair

    Journal of Dermatology Research

  5. Senescence-associated secretory phenotype (SASP) increases extracellular matrix remodeling.

    “contribute to extracellular matrix degradation, immune cell recruitment, and progressive weakening of the aneurysm wall.”

    Review

    Intracranial aneurysms as a manifestation of premature vascular aging: Cellular senescence, inflammaging, and wall degeneration

    Ageing research reviews

  6. Senescence-associated secretory phenotype (SASP) increases extracellular matrix remodeling.

    “cellular senescence exacerbates tissue damage through the senescence-associated secretory phenotype (SASP), which promotes inflammation and extracellular matrix degradation.”

    Review

    Circadian disruption and cellular senescence: emerging perspectives in periodontitis

    Odontology

  7. Senescence-associated secretory phenotype (SASP) increases extracellular matrix remodeling (persistent senescent cells and chronic SASP signaling).

    “when senescent cells persist, chronic SASP signaling can promote extracellular matrix remodeling”

    Reviewpersistent senescent cells and chronic SASP signalingtumor microenvironment

    The Implications of Radiotherapy-Induced Cellular Senescence for Cancer Treatment and Tumor Microenvironment Modulation

    International journal of biological sciences

  8. Senescence-associated secretory phenotype (SASP) increases extracellular matrix remodeling.

    “amplification of inflammation and extracellular matrix degradation via the senescence-associated secretory phenotype (SASP)”

    Review

    Chondrocyte Senescence in Osteoarthritis: Potential Targets and Pharmacological Interventions

    Cartilage

  9. Senescence-associated secretory phenotype (SASP) induces extracellular matrix remodeling in humans.

    “Aging causes an accumulation of senescent cells that secrete a range of cytokines, growth factors, and enzymes (SASPs), which remodel the ECM, making it stiffer and more degradable”

    Review

    Molecular Mechanisms Driving Metastatic Progression Within the Aged Tumor Microenvironment

    International journal of molecular sciences

  10. Senescence-associated secretory phenotype (SASP) increases extracellular matrix remodeling.

    “SASP contributes to the tumor environment by promoting inflammation, matrix remodeling, and tumor cell invasion.”

    Review

    Cellular senescence in the tumor with a bone niche microenvironment: friend or foe?

    Clinical and experimental medicine

More on Extracellular matrix remodeling

Immune evasion

upin reviews4upin humans1mediatesin reviews1

6 studies
  1. Senescence-associated secretory phenotype (SASP) mediates immune evasion (much of the evidence derives from preclinical models).

    “The senescence-associated secretory phenotype (SASP)-comprising IL-6, IL-8, TGF-β, and matrix metalloproteinases-serves as a central mediator linking cellular senescence to immune evasion and metastatic dissemination”

    Reviewmuch of the evidence derives from preclinical models

    Tumor immunosenescence drives breast cancer progression and therapeutic resistance: mechanisms and emerging interventions

    Frontiers in oncology

  2. Senescence-associated secretory phenotype (SASP) increases immune evasion (by reshaping the tumor microenvironment).

    “SASP factors contribute to tumor growth, metastasis, and immune evasion by reshaping the tumor microenvironment.”

    Reviewby reshaping the tumor microenvironment

    Multifacet Roles of Cellular Senescence in Cancer: Mechanisms and Therapeutic Implications

    MedComm – Oncology

  3. Senescence-associated secretory phenotype (SASP) increases immune evasion in tumors.

    “Within tumors, these alterations promote immune evasion through SASP-derived IL-6 and TGF-β”

    Reviewin tumors

    Immunosenescence and Cancer: Cellular Aging Programs That Reshape Antitumor Immunity

    Immune network

  4. Senescence-associated secretory phenotype (SASP) increases immune evasion.

    “SASP, comprising inflammatory cytokines such as IL-6 and IL-8 alongside matrix-remodeling factors, fosters immune evasion, angiogenesis and therapeutic resistance.”

    Review

    Cellular senescence in cancer: Unveiling dual roles, tumor microenvironment dynamics and therapeutic innovations (Review)

    Oncology letters

  5. Senescence-associated secretory phenotype (SASP) induces immune evasion in cancer.

    “These SASP secretions significantly reshape the TME, enabling cancer cells to evade immune destruction.”

    Reviewin cancer

    Harnessing the interaction between redox signaling and senescence to restrain tumor drug resistance

    Frontiers in cell and developmental biology

  6. Senescence-associated secretory phenotype (SASP) induces immune evasion.

    “SASP secretes cytokines, proteases, and growth factors, reshaping the tumor microenvironment (TME) to drive immune evasion, metastasis, and therapy resistance.”

    Review

    Senescence-associated secretory phenotype in lung cancer: remodeling the tumor microenvironment for metastasis and immune suppression

    Frontiers in oncology

Tissue damage

upin reviews2upin humans1

3 studies
  1. Senescence-associated secretory phenotype (SASP) increases tissue damage (chronic disease).

    “While its proinflammatory components drive tissue damage in chronic disease”

    Reviewchronic disease

    Silencing without clearing: pharmacological modulation of the SASP in aging and disease

    Frontiers in pharmacology

  2. Senescence-associated secretory phenotype (SASP) increases tissue damage (chronic accumulation of senescent cells).

    “creates a proinflammatory, profibrotic microenvironment through the senescence-associated secretory phenotype (SASP), thereby promoting tissue damage.”

    Reviewchronic accumulation of senescent cellsliver

    Targeting Cellular Senescence: A New Therapeutic Axis in Chronic Liver Disease

    Engineering

  3. Senescence-associated secretory phenotype (SASP) increases tissue damage in GCA and PMR.

    “We highlight how key SASP components, such as IL-6, IL-1β, and MMPs promote inflammation and tissue damage in GCA and PMR.”

    Reviewin GCA and PMR

    Cellular senescence in giant cell arteritis and polymyalgia rheumatica: From mechanisms to therapeutic opportunities

    European journal of clinical investigation

Immune response

mediatesin reviews2upin human cells1

3 studies
  1. Senescence-associated secretory phenotype (SASP) mediates immune response.

    “It promotes immune surveillance in the early stages of a tumor while inhibiting tumor immunity in its advanced stages.”

    Review

    The Role of Senescence, its Therapeutic Relevance and Clinical Implications in the Tumor Microenvironment

    Theranostics

  2. Senescence-associated secretory phenotype (SASP) mediates immune response.

    “the secretion of SASP by senescent neurons and glial cells in the central nervous system modulates the activity of immune cells.”

    Reviewcentral nervous system

    Senescence- and Immunity-Related Changes in the Central Nervous System: A Comprehensive Review

    Aging and disease

  3. Senescence-associated secretory phenotype (SASP) activates immune response in vitro.

    “the secretion of senescence-associated factors from mesenchymal cells stimulated the activation of T cells and natural killer cells and promoted epithelial cell senescence and cytotoxicity.”

    Cellsin vitro

    Senescence-associated secretory phenotypes in mesenchymal cells contribute to cytotoxic immune response in oral lichen planus

    Immunity & ageing : I & A

More on Immune response

Tumorigenesis

downin reviews1upin reviews1

2 studies
  1. Senescence-associated secretory phenotype (SASP) decreases tumorigenesis (transient SASP).

    “While transient SASP may enhance antitumor immunity and suppress early tumorigenesis”

    Reviewtransient SASP

    A Review of Senescence-Associated Secretory Phenotype-Mediated Remodeling of the Tumor Microenvironment: Implications for Cancer Progression and Therapy

    Cancer reports (Hoboken, N.J.)

  2. Senescence-associated secretory phenotype (SASP) increases tumorigenesis (unresolved output).

    “chronic ISR signaling and unresolved SASP output drive stem cell exhaustion, fibrosis, inflammation, and tumorigenesis.”

    Reviewunresolved output

    The Yin-Yang of Stress and Senescence: Integrated Stress Response and SASP Crosstalk in Stem Cell Fate, Regeneration, and Disease

    Biocell : official journal of the Sociedades Latinoamericanas de Microscopia Electronica ... et. al

More on Tumorigenesis

Osteoporosis

upin reviews1mediatesin reviews1

2 studies
  1. Senescence-associated secretory phenotype (SASP) increases osteoporosis within the inflammaging context.

    “the senescence-associated secretory phenotype (SASP) increases IL-6 and TNF-α, which stimulate immunosenescence, osteoporosis, rheumatoid arthritis erosions, and osteosarcopenia.”

    Reviewwithin the inflammaging context

    Interleukin-6 and tumor necrosis factor-α in osteoimmunology: Aging, and anticytokine therapies

    World Journal of Translational Medicine

  2. Senescence-associated secretory phenotype (SASP) mediates osteoporosis in aging.

    “senescence-associated secretory phenotype (SASP) mediating local and systemic deleterious effects on the skeleton”

    Reviewin aging

    Insights into age-related osteoporosis from senescence-based preclinical models and human accelerated aging paradigms

    Mechanisms of ageing and development

More on Osteoporosis

Tumor progression

upin reviews2

2 studies
  1. Senescence-associated secretory phenotype (SASP) increases tumor progression.

    “These secretions may promote chronic inflammation, tumor progression, metastasis, and resistance to anticancer therapy.”

    Review

    Targeting Cellular Senescence for Cancer Therapy

    International Journal of Innovative Science and Research Technology (IJISRT)

  2. Senescence-associated secretory phenotype (SASP) increases tumor progression.

    “it can promote tumor progression through the senescence-associated secretory phenotype (SASP)”

    Review

    Fate Bifurcation of Cellular Senescence: Dynamic Regulation from Tumor Suppression to Recurrence Risk

    Cells

More on Tumor progression

Metastasis

upin mice1upin reviews1

2 studies
  1. Senescence-associated secretory phenotype (SASP) increases metastasis (via SASP in melanoma).

    “yet also promote immune evasion, metastasis, and therapy resistance through SASP-mediated pathways”

    Reviewvia SASP in melanoma

    Role of Cellular Senescence in Melanoma: Implications for Tumor Progression and Therapy

    Anti-cancer agents in medicinal chemistry

  2. Senescence-associated secretory phenotype (SASP) increases metastasis in mice (40-70%).

    “accelerating metastasis by 40-70% in murine models”

    Review

    Deciphering the nexus of aging and pan-cancer: Single-cell sequencing reveals microenvironmental remodeling and cellular drivers

    Bioscience trends

Periodontal regeneration

downin humans1

1 study
  1. Senescence-associated secretory phenotype (SASP) impairs periodontal regeneration in humans (prior to periodontal regeneration surgery).

    “Sites expressing higher SASP expression in the GCF before periodontal regeneration achieved worse clinical and radiographic outcomes.”

    Human trialprior to periodontal regeneration surgerygingival crevicular fluid1-yearn = 40

    Impact of Inflammatory Markers and Senescence-Associated Secretory Phenotype in the Gingival Crevicular Fluid on the Outcomes of Periodontal Regeneration

    International journal of molecular sciences

More on Periodontal regeneration

All 144

Upstream

143

Cellular senescence

upin reviews10upin humans7downin human cells1upin human cells1

19 studies
  1. Cellular senescence induces senescence-associated secretory phenotype (SASP) in humans.

    “Senescence in the vascular cells, realized by the pathways p53/p21, p16INK4a/Rb and cGAS-STING, generates proinflammatory secretory phenotype (SASP)”

    Reviewvascular cells

    Cellular senescence, early vascular aging syndrome and subclinical atherosclerosis in young adults: an umbrella review

    Journal of Volgograd State Medical University

  2. Cellular senescence activates senescence-associated secretory phenotype (SASP).

    “senescence-prone glia expand and acquire SASP-rich transcriptional states”

    Reviewbrain

    Homeostatic conflict as a driver for brain aging

    Frontiers in genetics

  3. Cellular senescence activates senescence-associated secretory phenotype (SASP) in humans.

    “Senescent epithelial and stromal cells release cytokines, chemokines, growth factors, matrix-remodeling enzymes, and extracellular vesicles through the senescence-associated secretory phenotype (SASP).”

    Review

    Potential Roles of Cellular Senescence and Inflammaging in Prostate Cancer: Aging Microenvironment, Immune Remodeling, and Therapeutic Implications

    Cells

  4. Cellular senescence increases senescence-associated secretory phenotype (SASP).

    “Senescence is characterized by stable cell cycle arrest, metabolic alterations, chromatin remodelling and the secretion of pro-inflammatory and tissue-modifying factors that are collectively termed the senescence-associated secretory phenotype.”

    Review

    Genomic, epigenomic and transcriptomic regulation of cellular senescence

    Nature reviews. Genetics

  5. Cellular senescence increases senescence-associated secretory phenotype (SASP).

    “These dysfunctional microglia induce neighboring astrocytes into a neurotoxic state by releasing senescence-associated secretory phenotype factors.”

    Review

    Microglia-astrocyte crosstalk-driven metabolic-inflammatory imbalance and cerebrovascular frailty in exacerbating stroke injury during aging

    Experimental neurology

  6. Cellular senescence induces senescence-associated secretory phenotype (SASP).

    “senescent cells in the intestinal, hepatic, and vascular compartments generate the senescence-associated secretory phenotype (SASP)”

    Review

    Aging-driven metabolic abnormalities remodel intercellular communication through the gut-liver-heart axis and may promote coronary artery disease: the key role of bile acid metabolism

    Frontiers in immunology

  7. Cellular senescence decreases senescence-associated secretory phenotype (SASP) in senescent human fibroblasts.

    “Inflammatory SASP components were translationally depleted in senescence”

    Cellsin senescent human fibroblasts

    The Translatome of Senescent Cells Revealed by Sequencing Actively Translated mRNA

    bioRxiv : the preprint server for biologyPreprint

  8. Cellular senescence induces senescence-associated secretory phenotype (SASP).

    “The Senescence-Associated Secretory Phenotype (SASP) is demonstrated as broadcast from failed recursive return, linking inflammaging, fibrosis, immune exhaustion, tumor permissiveness, immunosenescence, and chronic disease”

    Review

    Immunity as Recursive Phase Closure and the Non-Returning State

    Zenodo (CERN European Organization for Nuclear Research)Preprint

  9. Cellular senescence increases senescence-associated secretory phenotype (SASP) in IVDD and OA.

    “Cellular senescence releases pro-inflammatory mediators and degradation enzymes via the senescence-associated secretory phenotype (SASP).”

    Reviewin IVDD and OA

    The common pathological network of inflammation, extracellular matrix imbalance, and senescence in intervertebral disc degeneration and osteoarthritis

    Molecular biology reports

  10. Cellular senescence activates senescence-associated secretory phenotype (SASP) in keloid pathology.

    “details the spatial heterogeneity of senescent cell accumulation, the activation and pathological effects of senescence-associated secretory phenotype (SASP)”

    Reviewin keloid pathology

    Cellular Senescence in Keloid Pathology: Mechanisms, Biomarkers, and Potential Therapeutic Targets

    Biomedicines

All 19

More on Cellular senescence

cGAS–STING signaling

upin reviews5mediatesin bovine cells1mediatesin cells1

7 studies
  1. cGAS–STING signaling increases senescence-associated secretory phenotype (SASP).

    “the overactivation of the cGAS-STING pathway is the core molecular mechanism driving the senescence-associated secretory phenotype (SASP)”

    Review

    Mitochondrial homeostasis and aging: the mtDNA-cGAS-STING axis

    Frontiers in immunology

  2. cGAS–STING signaling activates senescence-associated secretory phenotype (SASP).

    “damaged mitochondrial DNA leaks into the cytosol to activate the cyclic GMP-AMP synthase-stimulator of interferon genes pathway, amplifying the senescence-associated secretory phenotype”

    Review

    Mitochondria-Targeted Natural-Derived Compounds in Cellular Senescence: Mechanisms, Therapeutic Potential, and Future Directions

    Biology

  3. cGAS–STING signaling induces senescence-associated secretory phenotype (SASP).

    “triggering inflammatory programs including the senescence-associated secretory phenotype (SASP)”

    Review

    Cytosolic DNA sensing pathway in senescence and aging: Underlying mechanisms and targeted interventions

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

  4. cGAS–STING signaling mediates senescence-associated secretory phenotype (SASP) in cells.

    “the cGAS-STING pathway in mediating mtDNA release and SASP, respectively”

    Cells

    Mitochondrial DNA-driven senescence-associated secretory phenotype promotes the development of bronchopulmonary dysplasia

    American journal of physiology. Cell physiology

  5. cGAS–STING signaling induces senescence-associated secretory phenotype (SASP) (cellular senescence).

    “In cellular senescence, the cGAS-STING signaling pathway triggers the senescence-associated secretory phenotype, thereby exacerbating the senescence phenomenon”

    Reviewcellular senescence

    The cGAS-STING pathway in age-related ocular diseases: Mechanisms and therapeutic opportunities

    Cellular signalling

  6. cGAS–STING signaling increases senescence-associated secretory phenotype (SASP) in aging and neurodegenerative diseases.

    “Recent studies have identified an increasing role for activation of the cGAS-STING signaling pathway as a driver of senescence-associated secretory phenotypes (SASPs) in aging and NDDs.”

    Reviewin aging and neurodegenerative diseases

    Therapeutic targeting the cGAS-STING pathway associated with protein and gene: An emerging and promising novel strategy for aging-related neurodegenerative disease

    International immunopharmacology

  7. cGAS–STING signaling mediates senescence-associated secretory phenotype (SASP) in bovine cells (downstream of MSTN in bovine skeletal muscle cells).

    “Using cell signaling profiling, MSTN was shown to regulate the SASP, predominantly through the cycle GMP-AMP synthase-stimulator of antiviral genes (cGAS-STING) pathway.”

    Cellsdownstream of MSTN in bovine skeletal muscle cells

    Inactivation of Myostatin Delays Senescence via TREX1-SASP in Bovine Skeletal Muscle Cells

    International journal of molecular sciences

More on cGAS–STING signaling

STING1

mediatesin cells1is required forin human cells1upin human cells1

3 studies
  1. STING1 mediates senescence-associated secretory phenotype (SASP) in cells (downstream of oxidized DNA leakage in cholangiocytes).

    “resulting in the production and leakage of oxidized DNA, which facilitates the establishment of senescence-associated secretory phenotype (SASP) by activating STING”

    Cellsdownstream of oxidized DNA leakage in cholangiocytescholangiocyte

    Conjugated bile acids facilitate cholangiocyte senescence to promote cholestatic liver diseases via STING signaling

    Journal of advanced research

  2. STING1 is required for senescence-associated secretory phenotype (SASP) in aging, senescent and progeria fibroblasts, shown by cGAS and STING dependence.

    “aging/senescent/progeria cells activate inflammatory programs such as the senescence-associated secretory phenotype (SASP) and the interferon (IFN) response, in a cGAS and STING-dependent manner”

    Cellsin aging, senescent and progeria fibroblasts, shown by cGAS and STING dependence

    A non-canonical cGAS-STING pathway drives cellular and organismal aging

    bioRxiv : the preprint server for biologyPreprint

  3. STING1 increases senescence-associated secretory phenotype (SASP) in human cells (p < 0.01).

    “the increase was significantly suppressed by a knockdown of STING using siRNA (p < 0.01)”

    Cellsshown by siRNA knockdown in senescent biliary epithelial cells induced by serum depletion or GCDC4-7 days

    A heterogeneous subtype of biliary epithelial senescence may be involved in the pathogenesis of primary biliary cholangitis

    Clinics and research in hepatology and gastroenterology

More on STING1

Autophagy

downin cells1is required forin human cells1is required forin reviews1

3 studies
  1. Autophagy is required for senescence-associated secretory phenotype (SASP) (above a critical damage threshold).

    “Once this threshold is exceeded, autophagy is functionally reprogrammed to sustain the metabolic and biosynthetic demands of senescent cells, including production of the senescence-associated secretory phenotype (SASP).”

    Reviewabove a critical damage threshold

    The autophagy-senescence axis as a threshold model of aging and therapeutic targeting

    Redox biology

  2. Autophagy decreases senescence-associated secretory phenotype (SASP) in senescent NPCs.

    “Restoring autophagy reversed senescence by degrading GATA4, hence disrupting the SASP cascade.”

    Cellsin senescent NPCs

    Inhibition of OLR1 Reduces SASP of Nucleus Pulposus Cells by Targeting Autophagy-GATA4 Axis

    The journals of gerontology. Series A, Biological sciences and medical sciences

  3. Autophagy is required for senescence-associated secretory phenotype (SASP) in human cells during oncogene-induced senescence.

    “This process is important for sustaining senescence-associated metabolome and secretome alterations.”

    Cellsduring oncogene-induced senescence

    Selective degradation of ribosomes during oncogene-induced senescence: molecular insights and biological perspectives

    Autophagy

More on Autophagy

SIRT1

downin human cells1downin mouse cells1downin reviews1

3 studies
  1. SIRT1 decreases senescence-associated secretory phenotype (SASP) in cancer cells.

    “SIRT1 suppresses apoptosis, delays senescence, enhances mitochondrial function, and attenuates pro-inflammatory senescence-associated secretory phenotypes.”

    Reviewin cancer cells

    SIRT1-Mediated Redox and Senescence Regulation in Cancer: Mechanisms and Therapeutic Implications

    Antioxidants (Basel, Switzerland)

  2. SIRT1 decreases senescence-associated secretory phenotype (SASP) in mouse cells (downstream of 1,25(OH)2D3-enhanced Sirt1 expression).

    “which in turn reduced muscle cell senescence and the senescence-associated secretory phenotype (SASP) through decreased levels of acetylated nuclear p53 and p65”

    Cellsdownstream of 1,25(OH)2D3-enhanced Sirt1 expressionskeletal muscle

    Mesenchymal stem cell-specific Sirt1 overexpression prevents sarcopenia induced by 1,25-dihydroxyvitamin D deficiency

    Aging

  3. SIRT1 decreases senescence-associated secretory phenotype (SASP) in human cells (overexpression in Ang II-treated HASMCs).

    “the overexpression of SIRT1 diminished the levels of SASP-related proteins”

    Cellsoverexpression in Ang II-treated HASMCs

    A preliminary study of sirtuin-1 on angiotensin II-induced senescence and inflammation in abdominal aortic aneurysms

    CytoJournal

More on SIRT1

CDKN1A

upin human cells2no changein mouse cells1

3 studies
  1. CDKN1A induces senescence-associated secretory phenotype (SASP) in TFE3-rRCC.

    “nuclear CDKN1A/p21 induced cellular senescence (CS) and secretion of senescence-associated secretory phenotype (SASP) factors, particularly IL-6 and IL-8”

    Cellsin TFE3-rRCC

    Transcriptionally up-regulation of CDKN1A/p21 by TFE3 fusion proteins worsened TFE3-rearranged renal cell carcinoma

    Scientific reports

  2. CDKN1A increases senescence-associated secretory phenotype (SASP) in human cells.

    “p21Cip1 promotes the secretion of soluble ICAM-1, IL-1α, IL-6 and IL-8”

    Cells

    Loss of myosin light chain kinase induces the cellular senescence associated secretory phenotype to promote breast epithelial cell migration

    Scientific reports

  3. CDKN1A showed no clear effect on senescence-associated secretory phenotype (SASP) in mouse cells (RNAi knockdown during senescence).

    “RNAi knockdown of p21 during senescence in NIT-1 cells did not significantly impact viability or SASP”

    CellsRNAi knockdown during senescence

    Exploring Transcriptional Regulation of Beta Cell SASP by Brd4-Associated Proteins and Cell Cycle Control Protein p21

    Epigenomes

More on CDKN1A

NF-κB signaling

upin mice1upin reviews1

2 studies
  1. NF-κB signaling induces senescence-associated secretory phenotype (SASP) in mice.

    “Astrocytic NF-κB activation in young mice was able to mimic premature SASP formation but repressed Notch signaling in parallel.”

    Animalsastrocyte

    Aging mouse brains show opposing shifts in two cell signals

    Nucleic acids research

  2. NF-κB signaling activates senescence-associated secretory phenotype (SASP) (chronic SASP signaling in tumor microenvironment).

    “chronic SASP signaling driven by nuclear factor kB (NF-κB), CCAAT/enhancer-binding protein beta (C/EBPβ), and Signal Transducer and Activator of Transcription 3 (STAT3) fosters epithelial-to-mesenchymal transition (EMT), invasion, and therapy resistance.”

    Reviewchronic SASP signaling in tumor microenvironment

    Cellular senescence: Between protection and pathologies

    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society

More on NF-κB signaling

CCND1

upin mouse cells2

2 studies
  1. CCND1 increases senescence-associated secretory phenotype (SASP) in senescent cells.

    “We show that CCND1 and its kinase partner CDK6 drive SASP and ISG expression in senescent cells by promoting DNA damage accumulation.”

    Cellsin senescent cells

    Drug reduces frailty and improves performance in aged mice

    Nature aging

  2. CCND1 increases senescence-associated secretory phenotype (SASP) in senescent cells.

    “CCND1 and its kinase partner CDK6 drive SASP and ISG expression in senescent cells by promoting DNA damage accumulation.”

    Cellsin senescent cells

    Targeting CyclinD1-CDK6 to Mitigate Senescence-Driven Inflammation and Age-Associated Functional Decline

    bioRxiv : the preprint server for biologyPreprint

More on CCND1

ARG2

upin cells1upin human cells1

2 studies
  1. ARG2 induces senescence-associated secretory phenotype (SASP) in cells.

    “Accumulation of ARG2 subsequently activates mTOR and NF-κB signaling and thereby establishes a robust SASP”

    Cells

    m¹A-Dependent TRMT6/61A-ARG2 Axis Drives Protumorigenic Senescence by Remodeling the Tumor Microenvironment

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)

  2. ARG2 increases senescence-associated secretory phenotype (SASP) in human cells (lactate-treated OA-FLS; shown by siRNA knockdown).

    “high expression of senescence-associated secretory phenotype factors, which could be attenuated by siRNA-Arg2”

    Cellslactate-treated OA-FLS; shown by siRNA knockdown

    Lactate-upregulated ARG2 expression induces cellular senescence in fibroblast-like synoviocytes of osteoarthritis via activating the mTOR/S6K1 signaling pathway

    International immunopharmacology

More on ARG2

DNA damage response

upin humans1upin reviews1

2 studies
  1. DNA damage response induces senescence-associated secretory phenotype (SASP) in head and neck cancers.

    “Persistent DNA damage response (DDR) signaling drives SASP and thereby contributes to the progression of head and neck cancer”

    Reviewin head and neck cancers

    The Impact of Senescence-Associated Secretory Phenotype (SASP) on Head and Neck Cancers: From Biology to Therapy

    Cancers

  2. DNA damage response induces senescence-associated secretory phenotype (SASP).

    “These persistent cell cycle arrests initiated by DDR and other associated stress-induced signals promote a permanent state of cell cycle arrest called senescence-associated secretory phenotype (SASP).”

    Review

    Recent Advances in Anti-Aging Therapeutic Strategies Targeting DNA Damage Response and Senescence-Associated Secretory Phenotype-Linked Signaling Cascade

    Cell biochemistry and function

More on DNA damage response

All 143

Associations

77

Cancer

upin reviews5mixedin reviews1

6 studies
  1. Senescence-associated secretory phenotype (SASP) raises the risk of cancer (obesity).

    “Obesity-induced SASPs act as critical endocrine and paracrine signals that remodel tissue landscapes to be pro-tumorigenic.”

    Reviewobesity

    Remodeling the Immune Landscape: How Obesity-Induced SASPs Create a Pro-Tumorigenic Niche

    Current obesity reports

  2. Senescence-associated secretory phenotype (SASP) is associated with cancer (cancer microenvironment).

    “The SASP exerts profound and context-dependent effects on tumor initiation and progression.”

    Reviewcancer microenvironment

    Cellular senescence in cancer immunology and potential therapeutic strategy

    Frontiers in oncology

  3. Senescence-associated secretory phenotype (SASP) raises the risk of cancer (later via sustained SASP in precancer tissue microenvironment).

    “later contributing to a pro-tumoral precancer tissue microenvironment (PreTME) via a sustained, paracrine secretome known as senescent-associated secretory phenotype (SASP)”

    Reviewlater via sustained SASP in precancer tissue microenvironment

    Cellular senescence in precancer lesions and early-stage cancers

    Cancer cell

  4. Senescence-associated secretory phenotype (SASP) raises the risk of cancer (prolonged senescence in cancer cells).

    “prolonged senescence in cancer cells can drive tumorigenesis via the senescence-associated secretory phenotype”

    Reviewprolonged senescence in cancer cells

    Unraveling senescence in cancer: mechanistic complexities and therapeutic opportunities

    Molecular biology reports

  5. Senescence-associated secretory phenotype (SASP) raises the risk of cancer (through SASP factors influencing the tumor microenvironment).

    “Through these SASP factors influencing the tumor microenvironment, senescent cells can be deeply involved in various cancer pathologies such as carcinogenesis and the acquisition of drug resistance.”

    Reviewthrough SASP factors influencing the tumor microenvironment

    Senescence and Cancer

    Gan to kagaku ryoho. Cancer & chemotherapy

  6. Senescence-associated secretory phenotype (SASP) is associated with cancer.

    “senescence-associated secretory phenotype (SASP) is positively linked to tumorigenesis”

    Review

    Interactions between oxidative stress and senescence in cancer: Mechanisms, therapeutic implications, and future perspectives

    Redox biology

More on Cancer

Cellular senescence

upin silico2mixedin human cells1

3 studies
  1. Cellular senescence is associated with senescence-associated secretory phenotype (SASP) in silico (replicative senescence).

    “robust upregulation of canonical SASP-associated cytokines, chemokines, and matrix-related factors.”

    In silicoreplicative senescencefibroblasts

    Transcriptomic Insights into the Association of IL-1 Signaling with the Senescence-Associated Secretory Phenotype in Human Fibroblasts

    Genes

  2. Cellular senescence is associated with senescence-associated secretory phenotype (SASP) in silico.

    “Senescent MSCs displayed phenotypic changes, including altered morphology and the emergence of the Senescence-Associated Secretory Phenotype (SASP), which impaired regenerative potential.”

    In silicomesenchymal stem cells

    Investigation of the Molecular Signature of Senescence in Mesenchymal Stem Cells

    Avicenna journal of medical biotechnology

  3. Senescence-associated secretory phenotype (SASP) is associated with cellular senescence in vitro induced senescence.

    “we define and validate a 'core senescent profile' that might play a significant role in shaping the colon microenvironment.”

    Cellsin vitro induced senescencecolon

    Mapping the core senescence phenotype of primary human colon fibroblasts

    Aging

More on Cellular senescence

Type 2 diabetes

upin humans2

2 studies
  1. Type 2 diabetes is associated with senescence-associated secretory phenotype (SASP) in humans (T2DM-associated peri-implantitis vs peri-implantitis).

    “Compared to the control group, the level of SASPs was significantly higher in the T2DM-PI group”

    HumansT2DM-associated peri-implantitis vs peri-implantitisperi-implant crevicular fluid

    Clinical Significance of Aging-Related Secretory Phenotypic Factors in Diagnosing Type 2 Diabetes Mellitus-Associated Peri-Implantitis: A Retrospective Analysis

    British journal of hospital medicine (London, England : 2005)

  2. Type 2 diabetes is associated with senescence-associated secretory phenotype (SASP) in humans (sternal bone marrow-derived HSPCs of T2DM patients).

    “In line with our in vitro model, T2DM HSPCs were characterized by SASP profile and SETD7 upregulation.”

    Humanssternal bone marrow-derived HSPCs of T2DM patientsbone marrow

    Persistent epigenetic signals propel a senescence-associated secretory phenotype and trained innate immunity in CD34⁺ hematopoietic stem cells from diabetic patients

    Cardiovascular diabetology

More on Type 2 diabetes

Age-related diseases

upin reviews2

2 studies
  1. Senescence-associated secretory phenotype (SASP) is associated with age-related diseases.

    “Senescence and SASP are implicated in numerous age-related diseases.”

    Review

    The role of the dynamic epigenetic landscape in senescence: orchestrating SASP expression

    npj aging

  2. Senescence-associated secretory phenotype (SASP) raises the risk of age-related diseases.

    “SASP (senescence-associated secretory phenotype) that impairs tissue homeostasis and is involved in numerous age-related diseases.”

    Review

    Lipid remodeling in context of cellular senescence

    Biochimie

More on Age-related diseases

Coffee

downin humans1downin silico1

2 studies
  1. Coffee is associated with senescence-associated secretory phenotype (SASP) in humans (Long-term coffee consumers compared with coffee nondrinking subjects).

    “the levels of the senescence-associated secretory phenotype were lower in both long-term coffee consumers and new coffee consumers than in coffee nondrinking subjects”

    HumansLong-term coffee consumers compared with coffee nondrinking subjects

    Metabolic shifts during coffee consumption refresh the immune response: insight from comprehensive multiomics analysis

    MedComm

  2. Coffee is associated with senescence-associated secretory phenotype (SASP) in silico.

    “intake of cheese and coffee showed a negative correlation with SASPs”

    In silico

    Mendelian randomization study to assess causality between diet and phenotype of aging

    Asia Pacific journal of clinical nutrition

More on Coffee

KAT5

mixedin human cells1

1 study
  1. KAT5 is associated with senescence-associated secretory phenotype (SASP) in human cells (DNA damage-induced senescence).

    “the amplitude of the senescence-associated secretory phenotype (SASP) as measured by transcript and protein levels of secreted factors is dependent on the levels of TIP60.”

    CellsDNA damage-induced senescencenormal human fibroblast

    Protein levels alter drug sensitivity in lab-grown human cells

    bioRxivPreprint

More on KAT5

CD38

upin human cells1

1 study
  1. CD38 is associated with senescence-associated secretory phenotype (SASP) in donor lungs.

    “CD38 expression increased with donor age and ischemic stress, particularly in donation after circulatory death (DCD) allografts, and was associated with senescence-associated secretory phenotype (SASP) signaling.”

    Cellsin donor lungslung

    Blocking CD38 reduces lung transplant injury in mice

    Research SquarePreprint

More on CD38

Arterial stiffness

upin humans1

1 study
  1. Senescence-associated secretory phenotype (SASP) is associated with arterial stiffness in humans.

    “proinflammatory secretory phenotype (SASP), which is connected with destabilization of the atherosclerotic plaque, increased arterial stiffness and accelerated atherogenesis.”

    Review

    Cellular senescence, early vascular aging syndrome and subclinical atherosclerosis in young adults: an umbrella review

    Journal of Volgograd State Medical University

Homo sapiens

upin humans1

1 study
  1. Homo sapiens are associated with senescence-associated secretory phenotype (SASP) in IgG4-RD lesions.

    “demonstrated positive correlations between age and fibroblast, exhaustion, macrophage/M2, fibrosis-associated macrophage (FAM), inflammaging and senescence-associated secretory phenotype (SASP) signatures”

    Humansin IgG4-RD lesionslesion

    Inflammaging reshapes the immune ecosystem in IgG4-related dacryoadenitis and sialadenitis

    Rheumatology (Oxford, England)

More on Homo sapiens

Cancer progression

mixedin reviews1

1 study
  1. Senescence-associated secretory phenotype (SASP) is associated with cancer progression (described as a double-edged sword in cancer progression).

    “contributing to both tumor suppression and malignancy”

    Reviewdescribed as a double-edged sword in cancer progression

    Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level

    Aging and Cancer

More on Cancer progression

Periodontal regeneration

downin humans1

1 study
  1. Periodontal regeneration is associated with senescence-associated secretory phenotype (SASP) in humans (periodontal intrabony defects).

    “Teeth achieving COM presented significantly lower amounts of SASP factors compared with non-successful teeth.”

    Human trialperiodontal intrabony defectsgingival crevicular fluid1-yearn = 40

    Impact of Inflammatory Markers and Senescence-Associated Secretory Phenotype in the Gingival Crevicular Fluid on the Outcomes of Periodontal Regeneration

    International journal of molecular sciences

More on Periodontal regeneration

All 77

Funding

45 grants since 2016

Japan Society for the Promotion of Science¥137MNational Institute on Aging$3.6MNational Institute of Diabetes and Digestive and Kidney Diseases$2.1M

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Independent labs report that SASP induces senescence in rodent cells and that dasatinib plus quercetin reduces SASP in humans. SASP is associated with frailty in people with HIV and induces fibrosis when delivered into mouse lungs; a mouse result instead shows SASP increasing with dasatinib plus quercetin. Two trials ended over a year ago without posted results or linked papers.

  2. Summary rewritten as its findings changed.

    As it read before

    Independent labs reproduce SASP-induced senescence in mouse cells and SASP reductions with dasatinib plus quercetin in humans. A human study associates SASP with frailty in people with HIV. Rapamycin inhibits SASP in cells, whereas a human result reports no change.

  3. Summary rewritten as its findings changed.

    As it read before

    In human cell cultures, vertebrates, and mice, senolytics, lipid nanoparticles, and targeted compounds reduce senescence-associated secretory phenotype (SASP), whereas plastics and CCND2 activate it. Reviews associate SASP with inflammation, extracellular matrix remodeling, and impaired heart function.

  4. Summary written from the findings.

Latest

bioRxiv

Protein levels alter drug sensitivity in lab-grown human cells

Cells still stopped dividing after radiation, but protein levels changed their secreted signals and sensitivity to a drug that kills senescent cells.Cells still stopped dividing after radiation, but protein levels changed their secreted signals and sensitivity to a drug that kills senescent cells.

Preprint: human cell studyMechanisms
Cells

Cell-released particles reduce aging-linked signs in human cells

Stressed human heart-vessel lining cells showed fewer markers of senescence, a state in which cells stop dividing, after 48 hours of particle exposure in laboratory…Stressed human heart-vessel lining cells showed fewer markers of senescence, a state in which cells stop dividing, after 48 hours of particle exposure in laboratory experiments.

Human cell studyInterventions
International Journal of Molecular Sciences

Tobacco smoke makes mouse lung cells stop dividing

Experiments in mice linked smoke exposure to disrupted cell clocks and immune activation, alongside early changes that may leave lungs prone to scarring.Experiments in mice linked smoke exposure to disrupted cell clocks and immune activation, alongside early changes that may leave lungs prone to scarring.

Mouse studyLung

See all 4,588 papers on senescence-associated secretory phenotype (SASP)